Scopus
🔓 Açık Erişim YÖKSİS DOI Eşleşti
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science Immunology · Ağustos 2021
Özet
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or IFN-ω (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or IFN-ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases.
YÖKSİS Kayıtları
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science Immunology · 2021 SCI-Expanded
Prof. Dr. MELİKE EMİROĞLU →
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science Immunology · 2021 SCI-Expanded
Prof. Dr. JALE BENGİ ÇELİK →
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science Immunology · 2021 SCI-Expanded
Prof. Dr. JALE BENGİ ÇELİK →
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science Immunology · 2021 SCI-Expanded
Prof. Dr. JALE BENGİ ÇELİK →
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Science Immunology · 2021 SCI-Expanded
Doç. Dr. GÜLSÜM ALKAN →
Makale Bilgileri
Dergi
Science Immunology
Toplam Atıf
516 atıf
· Scopus
Yayın TarihiAğustos 2021
Cilt / Sayfa6
Scopus ID2-s2.0-85113517428
Erişim🔓 Açık Erişim
Kurumlar
Academy of Athens
Athens Greece
Aix Marseille Université
Marseille France
Amsterdam Neuroscience
Amsterdam Netherlands
AP-HM Assistance Publique - Hôpitaux de Marseille
Marseille France
AP-HP Assistance Publique - Hopitaux de Paris
Paris France
Bilkent Üniversitesi
Ankara Turkey
Center for Infection and Immunity of Lille (CIIL)
Lille France
Centre Hospitalier Lyon-Sud
Lyon France
Centre Hospitalier Universitaire de Saint-Étienne
Saint-Etienne France
Centro de Investigación Biomédica de La Rioja (CIBIR)
Logrono Spain
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
Madrid Spain
Charles University
Prague Czech Republic
CHU Averroes
Casablanca Morocco
CHU de Lyon
Lyon France
CHU Lille
Lille France
CNRS Centre National de la Recherche Scientifique
Paris France
Collège de France
Paris France
CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)
Barcelona Spain
École Normale Supérieure de Lyon
Lyon France
Etablissement Français du Sang
Saint-Denis-la-Plaine France
Faculté de Santé
Creteil France
Faculty of Medical Sciences, Goce Delcev University
Stip North Macedonia
Fakultní Nemocnice v Motole
Prague Czech Republic
Fundació Docència i Recerca MútuaTerrassa
Barcelona Spain
Garvan Institute of Medical Research
Sydney Australia
Graduate School of Medical and Dental Sciences
Tokyo Japan
Grand Hôpital de l'Est Francilien
Jossigny France
Hassan II University of Casablanca
Casablanca Morocco
Hiroshima University Graduate School of Biomedical and Health Sciences
Hiroshima Japan
Hopital Avicenne
Bobigny France
Hôpital Lariboisiere AP-HP
Paris France
Hôpital Necker Enfants Malades
Paris France
Hôpital Tenon
Paris France
Hôpital Universitaire Pitié Salpêtrière
Paris France
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria Spain
Hospital Universitari MútuaTerrassa
Terrassa Italy
Hospital Universitario Infanta Leonor
Madrid Spain
I. Horbachevsky Ternopil National Medical University
Ternopil Ukraine
Inserm
Paris France
Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS
Barcelona Spain
Institute for System Biology
Seattle United States
Institute for Systems Biology
Seattle United States
Institute of Public Health of the Republic of North Macedonia
Skopje North Macedonia
Institute of Science Tokyo
Tokyo Japan
Institute of Science Tokyo Hospital
Tokyo Japan
Institut Necker Enfants Malades
Paris France
Instituto de Salud Carlos III
Madrid Spain
Institut Pasteur de Lille
Lille France
Institut Pasteur, Paris
Paris France
IRCCS Ospedale San Raffaele
Milan Italy
Karolinska Institutet
Stockholm Sweden
Medizinische Universitat Innsbruck
Innsbruck Austria
MEPHI - Microbes, Evolution, Phylogénie et Infections
Marseille France
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda United States
National Referee Centre for Rheumatic
Lyon France
Necmettin Erbakan Üniversitesi
Meram Turkey
Northwell Health System
New York United States
Osakidetza, Donostia University Hospital
Donostia-San Sebastian Spain
PARCC - Paris-Centre de Recherche Cardiovasculaire
Paris France
Rioja Salud
Spain
Rockefeller University
New York United States
San Raffaele Scientific Institute
Milan Italy
San Raffaele Telethon Institute for Gene Therapy
Milan Italy
Santé Publique et Maladies Chroniques : Qualité de Vie Concepts, Usages et Limites, Déterminants
Marseille France
Shupyk National Healthcare University of Ukraine
Kyiv Ukraine
Spedali Civili Di Brescia
Brescia Italy
Tartu Ülikool
Tartu Estonia
Tel Aviv University
Tel Aviv-Yafo Israel
The University of British Columbia
Vancouver Canada
Uniformed Services University of the Health Sciences
Bethesda United States
Unité de Glycobiologie Structurale et Fonctionnelle (UGSF)
Villeneuve-d'Ascq France
Unité de Recherche sur les Maladies Cardiovasculaires, le Métabolisme et la Nutrition
Paris France
Universidad de Antioquia
Medellin Colombia
Universidad del Rosario
Bogota Colombia
Universidade de São Paulo
Sao Paulo Brazil
Università degli Studi di Milano-Bicocca
Milan Italy
Università degli Studi di Pavia
Pavia Italy
Universitair Ziekenhuis Gent
Ghent Belgium
Università Vita-Salute San Raffaele
Milan Italy
Université de Lille
Lille France
Université de Lyon
Lyon France
Université Jean Monnet Saint Etienne
Saint-Etienne France
Université Paris Cité
Paris France
University of California, San Francisco
San Francisco United States
UNSW Medicine
Kensington Australia
UNSW Sydney
Sydney Australia
Vall d'Hebron Institut de Recerca
Barcelona Spain
Vrije Universiteit Amsterdam
Amsterdam Netherlands
Son Atıflar
Systemic multi-omics analysis reveals interferon response heterogeneity and links lipid metabolism to immune alterations in severe COVID-19
Genome Medicine
· 2026 · DOI
Genetic contribution to severe COVID-19 in adults under 60 years without major comorbidities in the German National Pandemic Cohort Network (NAPKON)
Human Genomics
· 2026 · DOI
Systematic Review and Meta-analysis of Anti-interferon Auto-antibodies in Infectious Diseases
Journal of Clinical Immunology
· 2026 · DOI
Proteome-wide autoantibody screening and holistic autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape
BMC Immunology
· 2026 · DOI
Recent SARS-CoV-2 infections and increased antibody responses to viral antigens are associated with greater autoantibody reactivity
Immunology Letters
· 2026 · DOI
High risk of hypoxemic COVID-19 pneumonia in myasthenia gravis patients with type I IFN autoantibodies
Proceedings of the National Academy of Sciences of the United States of America
· 2026 · DOI
Autoantibodies against type I interferons in patients with zoonotic H7N9 influenza: an observational case–control study
Ebiomedicine
· 2026 · DOI
Analysis of West Nile disease convalescents identifies human monoclonal antibodies protective against West Nile and related orthoflaviviruses
Immunity
· 2026 · DOI
Auto-antibodies neutralizing type I interferons in ~10% of Moroccan patients with life-threatening COVID-19
Frontiers in Immunology
· 2026 · DOI
Clinical characteristics of autoantibodies neutralizing type I interferons in patients with coronavirus disease 2019 across phases of severe acute respiratory syndrome coronavirus 2 circulation
Respiratory Investigation
· 2026 · DOI
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 516.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Metrikler
516
Atıf